anx-510
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00081627)
Timeline
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(=O)c2c([nH]1)NCC1CN(c3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc3)CN21.[Ca+2]- Mol. weight
- 495.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103811 ↗
Also known as
- anx-510
- anx-510
- anx-510
- anx-510
- cofactor
- cofactor
- cofactor
- folitixorin calcium
- folitixorin calcium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00663481 | Phase 1 | Apr 1, 2008 | Mast Therapeutics, Parexel |
| NCT00337389 | Phase 3 | May 1, 2006 | Mast Therapeutics, Yale University |
| NCT00434369 | Phase 2 | Feb 1, 2006 | Mast Therapeutics |
| NCT00235898 | Phase 2 | May 1, 2005 | Mast Therapeutics, University of Glasgow |
| NCT00081627 | Phase 2 | Apr 1, 2004 | Mast Therapeutics, University of California, San Diego |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mast Therapeutics | For profit | 5 | 5 | 3 | 2004 |
| Parexel | For profit | 1 | 0 | 1 | 2008 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Glasgow | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2006 |
5 organizations
Page 1 / 1